Cammy Duong is a Vice President in ICR's Healthcare PR Practice. With more than 10 years of agency experience working with life science and healthcare companies, Cammy provides strategic counsel and tactical execution to tell the best story for the right audience at the right time. Passionate about storytelling and working collaboratively with journalists, Cammy helps create powerful narratives that center on healthcare innovation and improving human life.
Cammy’s breadth of experience across the financial, mainstream, patient and scientific communities has helped raise awareness for a variety of private and public companies and their respective disease spaces. Her client portfolio has included: Raptor Pharmaceuticals (acquired by Horizon Pharma), Optimer Pharmaceuticals (acquired by Cubist Pharmaceuticals), Trius Therapeutics (acquired by Cubist Pharmaceuticals), Impact Biomedicines (acquired by Celgene), Kala Pharmaceuticals, Nucleix, Gen-Probe (acquired by Hologic), Audentes (acquired by Astellas), Cepheid (acquired by Danaher), Halloran Consulting Group, Refuge Biotechnologies, Turning Point Therapeutics, Equillium and Xencor.
Prior to joining ICR, Cammy was an account director at Canale Communications, an Ashfield Healthcare Communications company and an account director at MacDougall Biomedical Communications. She received a B.A. in Journalism and Media Studies and a B.S. in Recreation Tourism Management with an emphasis on Sustainability from San Diego State University